Abstract: BACKGROUND: The definition of fever, and thus fever and neutropenia (FN), varies between different pediatric oncology centers. Higher temperature limit should reduce FN rates, but may increase rates of FN with complications by delaying therapy. This study determined if different fever definitions are associated with different FN rates. PROCEDURE: Two pediatric oncology centers had used three 39 [0.53-3.62]; P = 0.50). CONCLUSION: A higher fever definition was not associated with a lower FN rate, nor with an increased rate of FN with bacteremia. These may be false negative findings due to methodological limitations. These questions, with their potential impact on health-related quality of life, and on costs, need to be assessed in prospective studies. Pediatr Blood Cancer
INTRODUCTION
Fever and neutropenia (FN), specifically fever in severe chemotherapy-induced neutropenia, is the most frequent potentially lethal complication of chemotherapy in pediatric and adult patients with cancer [1] . The current management with emergency hospitalization and empirical administration of intravenous broadspectrum antibiotics has decreased mortality to below 1% in pediatric FN [2] . The two criteria defining FN directly influence whether the diagnosis of FN is made or not. These criteria thus have important implications on individual patient management, treatment-related mortality, and costs in pediatric oncology [3] . The first criterion, severe neutropenia, is quite uniformly defined and applied in pediatric oncology practice, as an absolute neutrophil count 0.5 G/L or 1.0 G/L and expected to rapidly decline [1] . The second criterion, however, the temperature limit defining fever, relevantly varies between different pediatric oncology centers, even within the same country [4] . The temperature limit clinically applied varied from 37.5 to 39.08C in 21 centers in the United Kingdom in 2005 [5] , and from 38.0 to 39.08C in 9 centers in Switzerland in 2012 (unpublished data). The temperature limit reported in 24 recently reviewed [6] original research articles on pediatric FN published in 2010 and 2011 varied as well from 37.5 to 39.08C (Fig. 1) . Current guidelines on the management of pediatric FN, developed by an international panel of 21 experts, do not discuss a temperature limit defining fever [7] .
By definition, the application of higher temperature limits defining FN should decrease the rate of FN diagnosed, but might increase the rate of FN with complicated bacterial infections because of delayed diagnosis and start of empirical antimicrobial therapy. We do not know of any published results of retrospective or prospective studies on such associations.
This study aimed to explore if different temperature limits defining fever were associated with differences in the rate of FN, and of FN with bacteremia, in pediatric patients with cancer.
METHODS

Study Design and Patients
This retrospective cohort study was conducted in two pediatric oncology centers in Switzerland. All children and adolescents up to 17 years diagnosed with a malignancy requiring chemotherapy between January 1, 2004 and June 30, 2011 were eligible for this study. Patients were identified through the centers' patient lists and the Swiss Childhood Cancer Registry. Information about chemotherapy, FN episodes, and 12 clinical characteristics potentially associated with FN (see Table I ) [1, 8] were extracted from patient charts by the first author (PB). This study was approved by the institutional review board with waiver of informed consent.
Definitions
Severe neutropenia was always defined as absolute neutrophil count 0.5 G/L [1, 2] . Different definitions for fever were used. In center 1, fever was defined throughout the entire study period as an ear temperature 38.58C persisting for 2 hours, without limit for a single temperature (low definition). In center 2, fever was [8] , and from July 9, 2007 to the end of the study period as a single ear temperature 398C (high). The maximum temperature measured at home or in the emergency department was used. If clinically indicated, the attending physicians in both centers were free to diagnose FN and to treat patients accordingly even if these temperature limits had not been reached.
FN was differentiated into episodes with and without bacteremia as a clinically important and well-defined complication. Aerobic and anaerobic blood cultures were taken at presentation with FN before starting antimicrobial therapy. Subsequent blood cultures were taken if patients remained febrile, or when they had shaking chills. Blood cultures were drawn from each lumen of existing central venous catheter, where applicable, or from peripheral venous lines. Peripheral and central cultures were not performed in parallel. Bacteremia was defined as at least one positive blood culture, irrespective of the pathogen detected, using a qualitative automated culture system (BacT/ALERT, bioMérieux, Geneva, Switzerland; or BACTEC, Becton Dickinson, Basel, Switzerland) [2, 9] .
Chemotherapy was classified into four levels of myelosuppressive intensity according to the expected duration of severe neutropenia: level 1, no severe neutropenia expected; levels 2 versus 3, 10 versus >10 days severe neutropenia expected; and level 4, myeloablative chemotherapy requiring autologous hematopoietic stem cell rescue [10, 11] . Myeloablative chemotherapy preceding allogeneic bone marrow transplantation was excluded from analysis. Chemotherapy exposure time was defined as the cumulative duration of chemotherapy plus 3 weeks accounting for neutropenia developing after cessation of chemotherapy [1, 8] . Because characteristics related to therapy and course of disease (e.g., chemotherapy intensity or relapse) could change over time, different observation periods per patient could be defined. During each observation period, all characteristics potentially associated with FN had to remain constant [8] .
Clinical Management of Fever in Neutropenia
During the entire study period, routine management for patients with cancer presenting with FN was emergency hospitalization and empirical broad-spectrum intravenous antimicrobial therapy. The first-line therapy was meropenem monotherapy in center 1, and a combination of ceftriaxone plus amikacin in center 2 [8] .
Measures to Increase Data Quality
Three measures were used in order to compensate for the drawbacks of the retrospective study design. First, the centers' patient lists were supplemented by information from the Swiss Childhood Cancer Registry in order to maximize patient coverage. Second, information on FN episodes from the prospective SPOG 2003 FN study [2, 9] , which had recruited patients from 2004 to 2007 in both centers, was used in order to maximize coverage of FN episodes. This information was as well used to calculate an improved estimate of the FN rate. Third, the senior author (RAA) made a plausibility check of data on chemotherapy intensity and duration.
Power Analysis
The second hypothesis, that is, that a higher fever definition may be associated with a higher rate of FN with bacteremia, was used for a one-sided power analysis on Poisson distributed data [12] . In order to reach 80% power, with alpha set at 5%, to detect a 50% increase of the FN rate with bacteremia (standardized difference, 0.5), 125 FN episodes with bacteremia were needed. Assuming a proportion of FN with bacteremia of 20% [1, 2] , this corresponded to 625 FN episodes in total. With an estimated cumulative annual incidence of 85 FN episodes in the two centers, the study had to cover 7.5 years, that is, January 2004 to June 2011. For FN the sample size of 625 FN episodes corresponds to around 90% power to detect a 25% increase of the FN rate (standardized difference, 0.25).
Statistical Analysis
Because of non-normally distributed data, medians, ranges, and interquartile ranges (IQR) were calculated for continuously measured variables. FN Poisson rates were calculated per month, together with their unconditional exact 95% confidence intervals (CI).
Associations of characteristics potentially associated with FN, and with FN with bacteremia, were assessed using univariate and multivariate mixed Poisson regression, with chemotherapy exposure time as rate multiplier, and with a random intercept per patient [8, 13] . For multivariate analysis, all characteristics statistically significant in univariate analysis, plus fever definition as the main variable of interest, were included into the model [12] . The characteristics center and year of chemotherapy start were not included in the multivariate model because of the important collinearity with fever definition.
P-values below 0.05 were considered significant. All analyses were performed using R 2.14.0 (R Foundation for Statistical Computing, Vienna, Austria). Specifically, the glmmPQL procedure was used for mixed Poisson regression [14] . [6] . The arrows indicate the three temperature limits studied here.
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RESULTS
Patients
A total of 521 patients were studied here, 310 (60%) treated in center 1, and 211 (40%) in center 2, and 217 (42%) were female.
The median age at diagnosis of malignancy was 5.9 years (range, 2 days to 16.8 years; IQR, 2.5-11.6 years). Diagnoses were acute lymphoblastic leukemia (ALL) in 161 (31%) patients, acute myeloid leukemia (AML) in 36 (7%), Hodgkin lymphoma in 41 (8%), Non-Hodgkin lymphoma in 33 (6%), solid tumors outside the 
Chemotherapy
The cumulative chemotherapy exposure time in these 521 patients was 182,886 days (6, 
Episodes of Fever in Neutropenia
During the cumulative chemotherapy exposure time of 6,009 months, 783 FN episodes were recorded (rate, 0.13 episodes per month; 95% CI, 0.12-0.14). Bacteremia was detected in 124 (16%) of these 783 FN episodes (rate, 0.021 per month; 95% CI, 0.017-0.025). Of the 521 patients, 302 (58%) had at least one FN episode (median per patient, 1; IQR, 0-2; range, 0-11), and 92 (18%) had at least one FN episode with bacteremia (median per patient, 0; range, 0-4). Death was considered to be caused by infection in five (0.6%) patients with FN episodes, four of them with bacteremia, and one with rhinocerebral mucormycosis [15] .
An improved estimate of the FN rate was calculated based on information from the second measure to increase data quality. 
Fever Definitions and the Risk to Develop FN
The rate of FN episodes per month was 0.15 (95% CI, 0.13-0.16) for the low fever definition. It was 0.13 (95% CI, 0.11-0.15) for the middle, and 0.10 (95% CI, 0.08-0.11) for the high definition (Table I) .
In univariate analysis, the high versus low fever definition was associated with a significantly lower FN rate (rate ratio, 0.66; 95% CI, 0.45-0.97; P ¼ 0.036; Table I ). Four of the remaining 11 characteristics, that is, diagnostic group (AML and solid tumor outside the CNS, respectively, vs. ALL), chemotherapy intensity (levels 2, 3, and 4 vs. level 1), bone marrow involvement, and the time period of chemotherapy start (2004/05 vs. 2010/11) were all significantly associated with an increased FN rate. The other seven characteristics, namely center, sex, age at diagnosis, relapse status, central venous access device, prior episodes of FN, and prior episodes of FN with bacteremia, were not significantly associated with the FN rate.
In multivariate analysis, when corrected for the three variables diagnostic group, chemotherapy intensity, and bone marrow involvement, fever definition was not significantly associated any more with the FN rate (high vs. low rate ratio, 0.94; 95% CI, 0.67-1.33; P ¼ 0.74; Table II ). Diagnostic group (Hodgkin lymphoma and CNS tumor, respectively, vs. ALL), and chemotherapy intensity (levels 2, 3, and 4 vs. level 1), were significantly and independently associated with the FN rate (Table II) . Nearly the entire variance was due to within-patient variance (t ¼ 0.000129, s ¼ 1.85).
Fever Definitions and the Risk to Develop FN With Bacteremia
The rate of FN episodes with bacteremia per month was 0.022 (95% CI, 0.017-0.028) for the low fever definition. It was 0.022 (95% CI, 0.014-0.033) for the middle, and 0.017 (95% CI, 0.011-0.024) for the high definition (Table III) .
In univariate analysis, the high versus low fever definition was not significantly associated with the rate of FN with bacteremia In multivariate analysis, when corrected for the three variables diagnostic group, chemotherapy intensity, and bone marrow involvement, fever definition was again not significantly associated with the rate of FN with bacteremia (high vs. low rate ratio, 1.39; 95% CI, 0.53-3.62; P ¼ 0.50; Table IV ). Neither diagnostic group nor bone marrow involvement was associated with the 
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rate of FN with bacteremia independently from chemotherapy intensity (Table IV) . Nearly the entire variance was due to within-patient variance (t ¼ 0.000307, s ¼ 2.03).
DISCUSSION
There is no consensus on how to define fever, and thus FN, in pediatric oncology. This is the first study to assess the association between different fever definitions and the rate of diagnosis of FN. In this retrospective two-center study in pediatric patients with cancer, a higher temperature limit defining fever was not associated with a reduced rate of FN diagnosed during chemotherapy. A significant reduction of about one-third of the FN rate was associated with the high versus low definition of fever, that is, a single temperature of 39.08C versus a temperature 38.58C persisting for 2 hours, only in univariate analysis (Table I) . When corrected for other FN risk factors in multivariate analysis, this reduction was not confirmed, and the FN rates in the three fever definitions studied were nearly equal, with quite narrow 95% CI (Table II) .
This finding would implicate that all children with a temperature 38.58C will reach as well a temperature 39.08C, which contradicts clinical experience. We do think, however, that this negative and counterintuitive result is due to three methodological limitations of this study: First, the three temperature limits defining fever studied here were all in a narrow range at the uppermost border of the spectrum of temperatures reported (Fig. 1) . This may lead to false negative results. Comparing temperature limits from opposite ends of the spectrum might increase the power to detect existing differences. Second, the different fever definitions were not independent from the centers: The low definition was only implemented in center 1, while the middle and the high definition were only implemented in center 2. Differences in the distribution of cancer diagnoses, in the proportion of FN diagnoses made clinically when the temperature limit defining fever was not reached, in chemotherapy, or in supportive therapy might systematically influence FN rates between centers besides fever definitions, allowing for important interaction effects. The temperature limits used clinically could not be reliably assessed in this retrospective study. It was not possible to directly estimate these interaction effects, but at least center itself was not associated with the FN rates. Third, the middle fever definition relied on axillary temperature measurements, while ear temperature measurements were used for the low and the high definitions. Compared to ear temperature, measured by infrared tympanic thermometry, axillary measurements are known to less reliably reflect core temperature, and to systematically result in lower findings by around 0.68C [16] . This may have reduced the differences in core temperature between different definitions. Specifically, this may have impaired those comparisons which included the middle definition, but not comparisons between the high and the low definitions.
Furthermore, the rates of FN with bacteremia were not significantly different in the three fever definitions studied in univariate or multivariate analysis (Tables III and IV) . Though the corresponding 95% CI were quite wide, a clinically relevant increase of 50% of the FN rate with bacteremia would have been detected with 80% power according to the results of the power analysis.
Wide and clinically relevant variations in fever definitions are known in pediatric oncology [5] , and these variations have a potentially large impact on individual patient management, mortality associated with FN, and costs [3] . Despite this, we do not know of any published results of research on the topic of this study. A comparison of its main results with those of other research groups is thus not possible.
Regarding secondary results, the FN rate of 0.13 per month of chemotherapy found here was comparable to the rate of 0.12 per month (1.48 per year) reported for the period from 1993 to 2004 in center 2 [8] . The proportion of FN episodes with bacteremia was 16% and thus within the range of 10-24% reported earlier [8, 9, [17] [18] [19] . The characteristics associated with FN with or without bacteremia found here, that is, AML diagnosis, higher intensity of chemotherapy, and bone marrow involvement, are all well-known risk factors for FN [1] . Interestingly, the finding of prior episodes of FN as an independent risk factor for FN and FN with bacteremia, reported from center 2 before [8] , could not be replicated here. 804 Binz et al.
Strengths of this study include its two-center design; its large size, with 521 patients representing the entire spectrum of pediatric malignancies, with a cumulative chemotherapy exposure time of 501 years, and with 783 FN, 124 of them FN with bacteremia; and the use of mixed Poisson regression as a powerful tool to analyze the specific kind of data studied. In addition to the three methodological limitations discussed above, the retrospective design of this study entails the risk of missing patients, plus missing and incorrect data. Three measures to increase data quality were used to minimize these problems.
In conclusion, a higher temperature limit defining fever was not associated with a reduced rate of FN diagnosed during chemotherapy in this study. Furthermore, a higher temperature limit was not associated with an increased rate of FN with bacteremia. The counterintuitive negative finding regarding the FN rate may well be a false negative finding due to methodological limitations. These might be overcome in adequately designed prospective studies on higher versus lower temperature limits defining fever and thus FN. If future research could show that a higher temperature limit is both efficacious, by reducing the rate of FN diagnosis, and safe, by not relevantly increasing the rate of FN with complications such as bacteremia, this would have an important impact on health-related quality of life in pediatric patients with cancer, and on costs.
